Open-Labeled, Randomized Multi-Center Phase II Study Evaluating the Efficacy and Safety of Paclitaxel/Carboplatin With and Without Cetuximab as First-Line Treatment of Adeno- and Undifferentiated Carcinoma of Unknown Primary (CUP).
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Cancer; Cancer metastases
- Focus Therapeutic Use
- Acronyms PACET-CUP
- 16 Jan 2013 New source identified and integrated (German Clinical Trials Register: DRKS00003677).
- 18 Dec 2009 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.
- 14 May 2009 New trial record